183 related articles for article (PubMed ID: 26040057)
21. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
Hyrich KL; Silman AJ
J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
[No Abstract] [Full Text] [Related]
23. Nonserious infections: should there be cause for serious concerns?
Dao KH; Herbert M; Habal N; Cush JJ
Rheum Dis Clin North Am; 2012 Nov; 38(4):707-25. PubMed ID: 23137578
[TBL] [Abstract][Full Text] [Related]
24. Graves' disease, rheumatoid arthritis, and anti-tumor necrosis factor-alpha therapy.
Shin JI; Kim MJ; Lee JS
J Rheumatol; 2009 Feb; 36(2):449-50; author reply 450. PubMed ID: 19208577
[No Abstract] [Full Text] [Related]
25. [TNF-alpha antagonist in rheumatoid arthritis. Joint destruction can be controlled].
MMW Fortschr Med; 2003 Oct; 145(41):46. PubMed ID: 14655484
[No Abstract] [Full Text] [Related]
26. Coxiella burnetii infection (Q fever) in rheumatoid arthritis patients with and without anti-TNFα therapy.
Schoffelen T; Kampschreur LM; van Roeden SE; Wever PC; den Broeder AA; Nabuurs-Franssen MH; Sprong T; Joosten LA; van Riel PL; Oosterheert JJ; van Deuren M; Creemers MC
Ann Rheum Dis; 2014 Jul; 73(7):1436-8. PubMed ID: 24794150
[No Abstract] [Full Text] [Related]
27. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.
Stokes MB; Foster K; Markowitz GS; Ebrahimi F; Hines W; Kaufman D; Moore B; Wolde D; D'Agati VD
Nephrol Dial Transplant; 2005 Jul; 20(7):1400-6. PubMed ID: 15840673
[TBL] [Abstract][Full Text] [Related]
28. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.
Gremese E; Carletto A; Padovan M; Atzeni F; Raffeiner B; Giardina AR; Favalli EG; Erre GL; Gorla R; Galeazzi M; Foti R; Cantini F; Salvarani C; Olivieri I; Lapadula G; Ferraccioli G;
Arthritis Care Res (Hoboken); 2013 Jan; 65(1):94-100. PubMed ID: 22730143
[TBL] [Abstract][Full Text] [Related]
29. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
30. [Lupus like syndrome induced by treatment with anti TNFalpha (infliximab): report of three cases].
Benucci M; Nenci G; Cappelletti C; Manfredi M
Recenti Prog Med; 2008; 99(7-8):363-6. PubMed ID: 18751615
[TBL] [Abstract][Full Text] [Related]
31. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
32. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
Bonafede MM; Gandra SR; Fox KM; Wilson KL
J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
[TBL] [Abstract][Full Text] [Related]
33. Tumor necrosis factor inhibitors for rheumatoid arthritis.
Scott DL; Kingsley GH
N Engl J Med; 2006 Aug; 355(7):704-12. PubMed ID: 16914706
[No Abstract] [Full Text] [Related]
34. Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab.
Diaz JC; Vallejo S; Cañas CA
Rheumatol Int; 2012 Oct; 32(10):3315-7. PubMed ID: 21881980
[TBL] [Abstract][Full Text] [Related]
35. Successful Etanercept Treatment for Primary Biliary Cirrhosis Associated with Rheumatoid Arthritis.
Kovács A; Siminischi AG; Baksay B; Gáll A; Takács M; Szekanecz Z
Isr Med Assoc J; 2015 Feb; 17(2):114-6. PubMed ID: 26223090
[No Abstract] [Full Text] [Related]
36. Development of autoimmune hepatitis in a child with systemic-onset juvenile idiopathic arthritis during therapy with etanercept.
Fathalla BM; Goldsmith DP; Pascasio JM; Baldridge A
J Clin Rheumatol; 2008 Oct; 14(5):297-8. PubMed ID: 18824922
[No Abstract] [Full Text] [Related]
37. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
[No Abstract] [Full Text] [Related]
38. Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis.
Boulton JG; Bourne JT
Rheumatology (Oxford); 2007 Jan; 46(1):178-9. PubMed ID: 16998233
[No Abstract] [Full Text] [Related]
39. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations].
Nasonov EL
Ter Arkh; 2007; 79(5):5-8. PubMed ID: 17672066
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
